Syeda Ayesha Shah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Syeda Ayesha Shah has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Hasan Mushahid
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan
3 shared publications - Syed Husain Farhan
Department of Surgery DOW University of Health Sciences Karachi Pakistan
2 shared publications - Asad Ali Siddiqui
Dow University of Health Sciences, Department of Medicine, Karachi, Pakistan
1 shared publication - George V. Moukarbel
Division of Cardiovascular Medicine, University of Toledo Medical Center, Toledo, Ohio, USA
1 shared publication - Huda Ahmed
Dow University of Health Sciences, Karachi, Pakistan
1 shared publication - Ishaque Hameed
Department of Medicine, MedStar Health, Baltimore, MD, USA
1 shared publication
Latest Publications
- Open Access
- 20 May 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (10) , e038987
National Trends in Heart Failure and Acute Myocarditis–Related Death Before and During the COVID‐19 Pandemic
Background: The COVID‐19 pandemic saw a rise in cardiovascular death, likely the result of disruptions in health care delivery and the infection itself. We examine mortality trends of heart failure (HF) and acute myocarditis (AM) before and during the pandemic and identify the most affected demographic subgroups. Methods and Results: We queried the Centers for Disease Control and Prevention Wide‐Ranging Online Data for Epidemiologic Research database for deaths from HF and AM before (1999–2019) and during (2020–2021) the COVID‐19 pandemic. Age‐adjusted mortality rates were calculated and stratified by sex, race and ethnicity, and age category. Trend‐level analysis was performed using the Joinpoint Regression Program, which estimates average annual percentage change (AAPC) in age‐adjusted mortality rate with corresponding 95% CI. A total of 7 366 944 HF deaths and 33 750 AM deaths occurred during 1999 to 2021. HF and AM mortality rates downtrended before the pandemic (AAPC, −0.63 and −2.42, respectively) but reversed during the pandemic (HF AAPC, 7.91; and AM AAPC, 20.3). Overall, during the pandemic, the age‐adjusted mortality rate for both HF and AM was greater for men, non‐Hispanic Black people, and adults aged ≥65 years. The sharpest increase was observed among non‐Hispanic American Indian people (AAPC, 14.9), Hispanic people (AAPC, 9.63), and young adults (AAPC, 20.9) for HF and among women (AAPC 18.7), non‐Hispanic Black people (AAPC, 15.6), and older adults (AAPC, 23.5) for AM. Conclusions: The prepandemic downward trends of HF and AM mortality rates have reversed since 2020. Subgroups that had the greatest absolute mortality rates from both AM and HF in the pandemic years were men, non‐Hispanic Black people, and older adults (aged ≥65 years).
- 20 May 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (10) , e038987
Open AccessNational Trends in Heart Failure and Acute Myocarditis–Related Death Before and During the COVID‐19 Pandemic
Background: The COVID‐19 pandemic saw a rise in cardiovascular death, likely the result of disruptions in health care delivery and the infection itself. We examine mortality trends of heart failure (HF) and acute myocarditis (AM) before and during the pandemic and identify the most affected demographic subgroups. Methods and Results: We queried the Centers for Disease Control and Prevention Wide‐Ranging Online Data for Epidemiologic Research database for deaths from HF and AM before (1999–2019) and during (2020–2021) the COVID‐19 pandemic. Age‐adjusted mortality rates were calculated and stratified by sex, race and ethnicity, and age category. Trend‐level analysis was performed using the Joinpoint Regression Program, which estimates average annual percentage change (AAPC) in age‐adjusted mortality rate with corresponding 95% CI. A total of 7 366 944 HF deaths and 33 750 AM deaths occurred during 1999 to 2021. HF and AM mortality rates downtrended before the pandemic (AAPC, −0.63 and −2.42, respectively) but reversed during the pandemic (HF AAPC, 7.91; and AM AAPC, 20.3). Overall, during the pandemic, the age‐adjusted mortality rate for both HF and AM was greater for men, non‐Hispanic Black people, and adults aged ≥65 years. The sharpest increase was observed among non‐Hispanic American Indian people (AAPC, 14.9), Hispanic people (AAPC, 9.63), and young adults (AAPC, 20.9) for HF and among women (AAPC 18.7), non‐Hispanic Black people (AAPC, 15.6), and older adults (AAPC, 23.5) for AM. Conclusions: The prepandemic downward trends of HF and AM mortality rates have reversed since 2020. Subgroups that had the greatest absolute mortality rates from both AM and HF in the pandemic years were men, non‐Hispanic Black people, and older adults (aged ≥65 years).
- 29 April 2024
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 24 (3) , 385-398
Differential Use of Glycoprotein IIb/IIIa Inhibitors with Bivalirudin in Patients with STEMI Undergoing PCI: A Systematic Review and Meta-Analysis
Aim The efficacy and safety of bivalirudin when used concurrently with glycoprotein IIb/IIIa inhibitors (GPI) is uncertain. In this systematic review and meta-analysis, we aimed to evaluate the efficacy and safety of bivalirudin versus heparin in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) and to explore the impact of differential use (greater and balanced) of GPI. Methods Online databases were queried from inception to March 2023 to identify eight randomized controlled trials (n = 22,483) for inclusion. The primary outcomes included all-cause mortality, major bleeding, major adverse cardiovascular events (MACE), and net adverse clinical events (NACE). Secondary efficacy endpoints included cardiac death, reinfarction, stent thrombosis (ST), and stroke. Data were pooled using a random-effects model to derive risk ratios (RRs) and 95% confidence intervals (CIs). Results When compared to heparin, bivalirudin was associated with a significant reduction in all-cause mortality (RR 0.83; 95% CI 0.72–0.97; P = 0.02), major bleeding (RR 0.73; 95% CI 0.57–0.93; P = 0.01), cardiac death (RR 0.79; 95% CI 0.66–0.94; P = 0.01), and NACE (RR 0.80; 95% CI 0.72–0.89; P < 0.0001). However, while the bivalirudin arm showed an increased likelihood of ST in the greater GPI subgroup (RR 1.70; 95% CI 1.13–2.56; P = 0.01), it was associated with a decreased likelihood of ST in the balanced GPI subgroup (RR 0.40; 95% CI 0.24–0.65; P = 0.0003). Conclusion Overall, our findings suggest that bivalirudin may be a more efficacious intervention than heparin for reducing certain adverse events in patients with STEMI undergoing primary PCI.
- 29 April 2024
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 24 (3) , 385-398
Differential Use of Glycoprotein IIb/IIIa Inhibitors with Bivalirudin in Patients with STEMI Undergoing PCI: A Systematic Review and Meta-Analysis
Aim The efficacy and safety of bivalirudin when used concurrently with glycoprotein IIb/IIIa inhibitors (GPI) is uncertain. In this systematic review and meta-analysis, we aimed to evaluate the efficacy and safety of bivalirudin versus heparin in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) and to explore the impact of differential use (greater and balanced) of GPI. Methods Online databases were queried from inception to March 2023 to identify eight randomized controlled trials (n = 22,483) for inclusion. The primary outcomes included all-cause mortality, major bleeding, major adverse cardiovascular events (MACE), and net adverse clinical events (NACE). Secondary efficacy endpoints included cardiac death, reinfarction, stent thrombosis (ST), and stroke. Data were pooled using a random-effects model to derive risk ratios (RRs) and 95% confidence intervals (CIs). Results When compared to heparin, bivalirudin was associated with a significant reduction in all-cause mortality (RR 0.83; 95% CI 0.72–0.97; P = 0.02), major bleeding (RR 0.73; 95% CI 0.57–0.93; P = 0.01), cardiac death (RR 0.79; 95% CI 0.66–0.94; P = 0.01), and NACE (RR 0.80; 95% CI 0.72–0.89; P < 0.0001). However, while the bivalirudin arm showed an increased likelihood of ST in the greater GPI subgroup (RR 1.70; 95% CI 1.13–2.56; P = 0.01), it was associated with a decreased likelihood of ST in the balanced GPI subgroup (RR 0.40; 95% CI 0.24–0.65; P = 0.0003). Conclusion Overall, our findings suggest that bivalirudin may be a more efficacious intervention than heparin for reducing certain adverse events in patients with STEMI undergoing primary PCI.
- 15 August 2023
- Published by Elsevier in Journal of Vascular Surgery: Venous and Lymphatic Disorders
- Vol. 11 (5) , 1083
Dabigatran for venous malformations: A call for a stringent approach
- 15 August 2023
- Published by Elsevier in Journal of Vascular Surgery: Venous and Lymphatic Disorders
- Vol. 11 (5) , 1083
Dabigatran for venous malformations: A call for a stringent approach